News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Beijing's BeiGene (BGNE) Raises $200 Million In A Secondary Offering



11/23/2016 9:26:30 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
BeiGene, a Beijing novel oncology biopharma, completed a $200 secondary offering last week, up from its initial target of $150 million. The $200 million included $15 million from selling shareholders. In February, BeiGene raised $158 million in a NASDAQ IPO, and it reported $200 million in cash at the end of the third quarter. BeiGene is currently running clinical trials on four novel cancer drug candidates, and its costs have risen as a result: the company reported a loss of $80 million in the first nine months of 2017.

Read at ChinaBio Today


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES